Loading
A phase 3 trial of Pembrolizumab, Epacadostat, Sunitinib and Pazopanib in Renal cell carcinoma, run by Incyte Corporation, completed.
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) is a phase 3 interventional study registered as NCT03260894 by Incyte Corporation, with 129 participants recorded, started 2017-12-07 and reaching its primary completion in 2018-08-22. Interventions recorded: Pembrolizumab, Epacadostat, Sunitinib, Pazopanib. Conditions recorded: Renal Cell Carcinoma (RCC).
Linked to the drug Epacadostat because the registry names it among its interventions and Renal cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
129 enrolled.
95% CI 20.2 to 44.1; Figures from the ClinicalTrials.gov results section (first posted 2019-09-10), not from a publication · 95% CI 18.6 to 41.8
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) of Pembrolizumab + Epacadostat Versus Standard of Care (SOC), Objective Response (CR+PR)primary | Pembrolizumab + Epacadostat | 64 | 31.3% | - | - | link |
| SoC (Sunitinib or Pazopanib) | 65 | 29.2% |
Shares Epacadostat, Incyte, Pembrolizumab and the tag pipeline.
Shares Epacadostat, Incyte and the tag pipeline.
Shares Incyte and the tag pipeline.
Shares Sunitinib, Renal cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma, Pembrolizumab and the tag pipeline.
Shares Renal cell carcinoma, Pembrolizumab and the tag pipeline.
Shares Renal cell carcinoma, Pembrolizumab and the tag pipeline.
Shares Incyte and the tag pipeline.